Tocilizumab, Remdesivir, Favipiravir, and Dexamethasone Repurposed for COVID-19: a Comprehensive Clinical and Pharmacovigilant Reassessment
Mina Kelleni
Topics & Concepts
FavipiravirTocilizumabMedicineDexamethasoneCoronavirus disease 2019 (COVID-19)Clinical trialClinical endpointIntensive care medicinePandemicInternal medicineDiseaseInfectious disease (medical specialty)COVID-19 Clinical Research StudiesLong-Term Effects of COVID-19SARS-CoV-2 and COVID-19 Research